XY028-140

• Description :

  XY028-140 is a PROTAC connected by ligands for Cereblon and CDK. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  CDK; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; PROTAC

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/xy028-140.html

• Purity :

  98.52

• Solubility :

  DMSO : 5.56 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1C2=C(C(N1C3C(NC(CC3)=O)=O)=O)C(NCC(N4CCN(CC4)C5=CN=C(NC6=NC(N(C7CCCC7)C(C(C(C)=O)=C8C)=O)=C8C=N6)C=C5)=O)=CC=C2

• Molecular Formula :

  C39H40N10O7

• Molecular Weight :

  760.80

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1.|[2]Xuewei Wu, et al. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nat Cancer 2, 429-443 (2021) .

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK4; CDK6; Cereblon

• CAS Number :

  [2229974-83-6]